The assessment of surface dose is essential in radiotherapy to avoid deterministic effect or to
reduce the severity of side effects from radiation treatment. In this study, the surface dose for breast
cancer radiotherapy was measured using two types of dosimeter; Thermoluminescent Dosimeter
(TLD) and Optically Stimulated Luminescent Dosimeter (OSLD). The study was performed on the
left breast of female Alderson Radiation Therapy (ART) phantom. The treatment planning was
carried out on the ART phantom to determine the homogeneity of dose distribution within the target
organ is complied with the tolerance limits of 95% to 107% as recommended by the International
Commission on Radiation Units and Measurements (ICRU)’s Report No. 50. From the treatment
planning result, the phantom then was irradiated with 267 cGy dose per fraction for two beam
fields; medial tangential and lateral tangential fields using a 6 MV photon beam produced from
three-dimensional (3D) conformal radiotherapy. Result shows that the OSLD provides 25.7% and
23.5% higher surface dose compared to TLD for medial tangential and lateral tangential fields,
respectively. This condition may be due to higher effective point of measurement and angular
dependence of the OSLD compared to TLD. As a conclusion, suitable dosimeter should be selected
to ensure accurate estimation of surface dose could be made thus reduction of skin reaction to
patient could be achieved.
This study characterises and evaluates an Al2O3:C-based optically stimulated luminescent dosemeter (OSLD) system, commercially known as the nanoDot™ dosemeter and the InLight® microStar reader, for personal and in vivo dose measurements in diagnostic radiology. The system characteristics, such as dose linearity, reader accuracy, reproducibility, batch homogeneity, energy dependence and signal stability, were explored. The suitability of the nanoDot™ dosemeters was evaluated by measuring the depth dose curve, in vivo dose measurement and image perturbation. The nanoDot™ dosemeters were observed to produce a linear dose with ±2.8% coefficient variation. Significant batch inhomogeneity (8.3%) was observed. A slight energy dependence (±6.1%) was observed between 60 and 140 kVp. The InLight® microStar reader demonstrated good accuracy and a reproducibility of ±2%. The depth dose curve measured using nanoDot™ dosemeters showed slightly lower responses than Monte Carlo simulation results. The total uncertainty for a single dose measurement using this system was 11%, but it could be reduced to 9.2% when energy dependence correction was applied.
This study investigates the characteristics and application of the optically-stimulated luminescence dosimeter (OSLD) in cobalt-60 high dose rate (HDR) brachytherapy, and compares the results with the dosage produced by the treatment planning system (TPS). The OSLD characteristics comprised linearity, reproducibility, angular dependence, depth dependence, signal depletion, bleaching rate and cumulative dose measurement. A phantom verification exercise was also conducted using the Farmer ionisation chamber and in vivo diodes. The OSLD signal indicated a supralinear response (R2 = 0.9998). It exhibited a depth-independent trend after a steep dose gradient region. The signal depletion per readout was negligible (0.02%), with expected deviation for angular dependence due to off-axis sensitive volume, ranging from 1 to 16%. The residual signal of the OSLDs after 1 day bleached was within 1.5%. The accumulated and bleached OSLD signals had a standard deviation of ± 0.78 and ± 0.18 Gy, respectively. The TPS was found to underestimate the measured doses with deviations of 5% in OSLD, 17% in the Farmer ionisation chamber, and 7 and 8% for bladder and rectal diode probes. Discrepancies can be due to the positional uncertainty in the high-dose gradient. This demonstrates a slight displacement of the organ at risk near the steep dose gradient region will result in a large dose uncertainty. This justifies the importance of in vivo measurements in cobalt-60 HDR brachytherapy.